We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sanofi has announced that it will invest $476 million in a multi-vaccine manufacturing facility in Singapore to mass produce vaccines for the Asian market. Read More
Eli Lilly has revised its supply deal with the U.S. government to focus on distributing the company’s COVID-19 antibody bamlanivimab along with another antibody, etesevimab — a combination that has proven to be effective against variant strains of the Sars-CoV-2 virus which causes COVID-19 infections. Read More
More harmful side effects were found in clinical study reports submitted to regulators than in listings about the same medicines in trial registries or published studies. Read More
Regeneron Pharmaceuticals has said its COVID-19 antibody cocktail, REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic infections by 81 percent in a late-stage trial. Read More
In a much-needed development, Johnson & Johnson began delivery of its one-shot COVID-19 vaccine within the EU yesterday as the trade bloc continues to clamor for enough doses to inoculate its 446 million residents. Read More
The FDA has selected Patrizia Cavazzoni as permanent director of the Center for Drug Evaluation and Research (CDER), a position previously held for many years by Acting Commissioner Janet Woodcock. Read More
The U.K.’s National Institute for Health and Care Excellence (NICE) has issued a preliminary rejection of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) as a combination treatment for lung cancer in as-yet untreated patients. Read More